CARB-X backs Swiss Polyphor

CARB-X backs Swiss Polyphor

  • 04/02/2019

CARB-X is providing funding for the further development of Polyphor’s new class of Outer Membrane Protein Targeting Antibiotics (OMPTA).

Boston-based AMR accelerator CARB-X is awarding Swiss Polyphor up to $2.6 million in non-dilutive funding with the possibility of $3.0 million more if certain project milestones are met, to develop a novel antibiotic with a novel mode of action to treat serious infections caused by Gram-negative ESKAPE pathogens.

“The world urgently needs new classes of antibiotics, like those that Polyphor is developing, to treat life-threatening infections,” said Kevin Outterson, Executive Director of CARB-X and Boston University law professor. “Polyphor’s OMPTA project represents a promising new approach to treating infections caused by the deadliest drug-resistant bacteria. CARB-X is providing funding as well as technical and business support through our expanding network of accelerators. The projects in the powered by CARB-X portfolio are in the early stages of development, but if successful, they offer tremendous hope in the global fight against drug resistance.”

Giacomo Di Nepi, Chief Executive Officer of Polyphor, said: “We are delighted to have the support of CARB-X, which will enable us to accelerate and further advance our preclinical candidate targeting resistant Gram-negative bacteria. CARB-X supports the best science and most promising early development R&D projects in the world to prevent and treat life-threatening bacterial infections and we are honored to have been selected in a highly competitive evaluation process.”

Polyphor’s new class of outer-membrane protein targeting antibiotics displays potent activity against bacteria referred to as Gram-negative ESKAPE pathogens (Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species). Importantly, this new class is active against strains which have become resistant to most antibiotics including the last-resort antibiotic colistin. CARB-X funding will help support preclinical development and potentially Phase 1 clinical trials.